Abstract | OBJECTIVE: DESIGN: Prospective experimental study. SETTING: University hospital laboratory. SUBJECTS: Male New Zealand White rabbits (n = 75). INTERVENTIONS: S. pneumoniae (16089 strain; minimal inhibitory concentration for moxifloxacin = 0.125 mg/L) was instilled intrabronchially. Four hours later, a human-like moxifloxacin treatment was initiated in spontaneously breathing (SB) and mechanically ventilated (MV) animals. Untreated rabbits were used as controls. Survivors were killed 48 hrs later. Pneumonia was assessed and moxifloxacin pharmacokinetics were analyzed. MEASUREMENTS AND MAIN RESULTS:
Moxifloxacin treatment was associated with an improvement in survival in the SB animals (13 of 13 [100%] vs. eight of 37 [21.6%] controls). The survival rate was less influenced by treatment in MV rabbits (seven of 15 [46.1%] vs. one of eight [12.5%] controls). The lung bacterial burden was greater in MV compared with SB rabbits (5.1 +/- 2.4 vs. 1.6 +/- 1.4 log10 colony-forming units/g, respectively). Nearly all the untreated animals presented bacteremia as reflected by a positive spleen culture. No bacteremia was found in SB animals treated with moxifloxacin. In contrast, three of 13 (23.1%) moxifloxacin-treated and MV animals had positive spleen cultures. The apparent volume of distribution of moxifloxacin was lower in MV compared with SB rabbits. CONCLUSIONS:
|
Authors | Pierre Emmanuel Charles, Manuel Etienne, Delphine Croisier, Lionel Piroth, Catherine Lequeu, Jerome Pugin, Henri Portier, Pascal Chavanet |
Journal | Critical care medicine
(Crit Care Med)
Vol. 33
Issue 5
Pg. 1029-35
(May 2005)
ISSN: 0090-3493 [Print] United States |
PMID | 15891332
(Publication Type: Journal Article)
|
Chemical References |
- Aza Compounds
- Fluoroquinolones
- Quinolines
- Moxifloxacin
|
Topics |
- Animals
- Area Under Curve
- Aza Compounds
(blood, pharmacokinetics, therapeutic use)
- Community-Acquired Infections
(drug therapy, microbiology)
- Disease Models, Animal
- Fluoroquinolones
- Half-Life
- Male
- Moxifloxacin
- Pneumococcal Infections
(drug therapy, microbiology)
- Quinolines
(blood, pharmacokinetics, therapeutic use)
- Rabbits
- Respiration, Artificial
(adverse effects)
|